Revision of the agreement between Eli Lilly and Co. and Cor Therapeutics Inc. (CORR), announced last week, is the fifth research collaboration Lilly has amended in the past six months as the pharma company streamlines its research programs.

A Lilly spokesperson said its research now is focused on cardiovascular disease, bacterial and viral infections, cancer, central nervous system disorders, diabetes, lung disorders and bone diseases.